Two apolipoprotein E5 variants illustrate the importance of the position of additional positive charge on receptor-binding activity
Open accessAbstract
Apolipoprotein (apo) E polymorphism has a significant effect on plasma cholesterol and low density lipoprotein cholesterol concentrations. The association of two apoE5 isoforms with elevated plasma low density lipoprotein cholesterol levels in two unrelated subjects led us to investigate the primary structures and receptor-binding properties of their apoE. Cysteamine modification and isoelectric focusing demonstrated that the apoE5 isoform from subject 1 did not contain cysteine but that the apoE5 isoform from subject 2 contained one residue of cysteine. The structural mutation in the apoE5 isoform of subject 1 was determined by peptide sequencing. Like apoE4, this variant had arginine at position 112 but differed from apoE4 by the substitution of arginine for proline at position 84. When purified and subjected to a competitive binding assay, this apoE5(84 Pro----Arg, 112 Cys----Arg) variant had the same receptor-binding activity as normal apoE3. Because subject 2 was of Japanese descent and her apoE5 contained one cysteine residue, we suspected that it would contain the lysine-forglutamic acid mutation at position 3 that has been described previously in Japanese subjects. This was confirmed by directly sequencing the first 10 amino acid residues of her apoE. When subjected to the competitive binding assay, the total apoE from subject 2, which consisted of approximately equal amounts of normal apoE3 and apoE5(3 Glu----Lys), had a binding activity of 188%, confirming the previously reported enhanced binding of this variant. These results demonstrate that the enhancement of receptor-binding activity of more basic isoforms of apoE depends on the position at which additional positively charged amino acids are incorporated.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A few rare apo E variants (p.Glu21Lys, p.Pro102Arg, p.Leu270Glu) have been observed in probands with hyperLDLemia, but none co-segregated with hyperLDLemia in the families.
“a few rare apo E variants (p.Glu21Lys, p.Pro102Arg and, p.Leu270Glu) have been observed in probands with hyperLDLemia (type IIa hyperlipoproteinemia), but none co-segregated with hyperLDLemia in the families (Wardell MR et al. 1991, van den Maagdenberg AM et al. 1993).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the<i>APOE</i>p.Leu167del Mutation (2013) · cites this paper as Wardell MR et al. 1991
The p.Arg269Gly apo E mutant has been previously reported in a proband with type IIb hyperlipoproteinemia, differing from ADH by elevated plasma triglyceride levels.
“The p.Arg269Gly apo E mutant has been previously reported in a proband with type IIb hyperlipoproteinemia, differing from ADH by elevated plasma triglyceride levels (Wardell MR et al. 1991).”
From Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with the<i>APOE</i>p.Leu167del Mutation (2013) · cites this paper as Wardell MR et al. 1991
APOE5 (Pro84Arg,Cys112Arg) heterozygosity was found in a 54-year-old woman of European descent with elevated LDL cholesterol levels.
“Furthermore, APOE5 (Pro84Arg,Cys112Arg) heterozygosity was found in a 54-year-old woman of European descent with elevated LDL cholesterol levels113).”
From Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features (2025) · cites this paper as [113]
The pathogenic mechanisms underlying HLP in patients with apoE5 (Glu3Lys) are presumed to involve downregulation of LDL receptors due to high uptake of lipoproteins containing this apoE mutant.
“The pathogenic mechanisms underlying HLP in patients with apoE5 (Glu3Lys) are presumed to involve downregulation of low-density lipoprotein (LDL) receptors due to high uptake of lipoproteins containing this apoE mutant [10,11].”
From A case of lipoprotein glomerulopathy with a rare apolipoprotein E isoform combined with neurofibromatosis type I (2018) · cites this paper as [11]
Cites
Apolipoprotein E polymorphism and atherosclerosis.
Davignon, J., Gregg, R. E., & Sing, C. F. (1988) · Arteriosclerosis: An Official Journal of the American Heart Association, Inc. · doi:10.1161/01.atv.8.1.1 · Cited by 1,981 · see citing works
Human apolipoprotein E. The complete amino acid sequence
Rall, S. C., Weisgraber, K. H., & Mahley, R. W. (1982) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)34702-1 · Cited by 741 · see citing works
Self-citationAbnormal in vivo metabolism of apolipoprotein E4 in humans.
Gregg, R. E., Zech, L. A., Schaefer, E. J., Stark, D., Wilson, D., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112645 · Cited by 345 · see citing works
Self-citationFamilial apolipoprotein E deficiency.
Schaefer, E. J., Gregg, R. E., Ghiselli, G., Forte, T. M., Ordovas, J. M., Zech, L. A., & Brewer, H. B. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112704 · Cited by 313 · see citing works
Self-citationWeisgraber, K. H. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)42621-5 · Cited by 304 · see citing works
Self-citationWardell, M. R., Brennan, S. O., Janus, E. D., Fraser, R., & Carrell, R. W. (1987) · Journal of Clinical Investigation · doi:10.1172/jci113096 · Cited by 159 · see citing works
Self-citationWardell, M. R., Weisgraber, K. H., Havekes, L. M., & Rall, S. C. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)30067-5 · Cited by 80 · see citing works
Self-citationAnalysis of Apolipoprotein E5 Gene from a Patient with Hyperlipoproteinemia1
Tajima, S., Yamamura, T., & Yamamoto, A. (1988) · The Journal of Biochemistry · doi:10.1093/oxfordjournals.jbchem.a122420 · Cited by 42 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Apolipoprotein E: Structure-Function Relationships
Weisgraber, K. H. (1994) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60642-7 · Cited by 830 · see citing works
Self-citationAPOE gene variants in primary dyslipidemia
Khalil, Y. A., Rabès, J.-P., Boileau, C., & Varret, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.05.007 · Cited by 170 · see citing works
Marduel, M., Ouguerram, K., Serre, V., Bonnefont-Rousselot, D., Marques-Pinheiro, A., Erik Berge, K., Devillers, M., Luc, G., Lecerf, J.-M., Tosolini, L., et al. (2013) · Human Mutation · doi:10.1002/humu.22215 · Cited by 133 · see citing works
Orth, M., Weng, W., Funke, H., Steinmetz, A., Assmann, G., Nauck, M., Dierkes, J., Ambrosch, A., Weisgraber, K. H., Mahley, R. W., et al. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.5.1306 · Cited by 42 · see citing works
Self-citationFeussner, G., Scharnagl, H., Scherbaum, C., Acar, J., Dobmeyer, J., Lohrmann, J., Wieland, H., & März, W. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)39106-9 · Cited by 21 · see citing works
Impact of Apolipoprotein E Variants: A Review of Naturally Occurring Variants and Clinical Features
Matsunaga, A., & Saito, T. (2025) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.65393 · Cited by 14 · see citing works
Takasaki, S., Matsunaga, A., Joh, K., & Saito, T. (2018) · CEN Case Reports · doi:10.1007/s13730-018-0309-2 · Cited by 7 · see citing works
- Authors
- Wardell, M., Rall, S., Schaefer, E., Kane, J., & Weisgraber, K.
- Affiliations
- University of California, San Francisco (US)
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 1991-03
- Volume
- 32
- Issue
- 3
- Pages
- 521-528
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2138870569
- Cited by
- 40
- References
- 8
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2022: 2 · 2021: 2 · 2018: 2 · 2017: 2 · 2016: 1 · 2015: 2 · 2012: 1
- FWCI
- 4.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL-41633, P01HL041633)
- Topics
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- apolipoprotein E, APOE polymorphism, receptor binding activity, cysteine substitution, arginine substitution, LDL cholesterol, serum cholesterol
- MeSH terms
- Amino Acids, Apolipoproteins E, Female, Humans, Isoelectric Focusing, Middle Aged, Polymorphism, Genetic, Receptors, Cell Surface, Low Density Lipoprotein Receptor-Related Protein-1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review